The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors  

作　　者：Alan D Guerrero Judy S Moyes Laurence JN Cooper 

机构地区：[1]Division of Pediatrics,The University of Texas MD Anderson Cancer Center [2]The University of Texas Graduate School of Biomedical Sciences

出　　处：《Chinese Journal of Cancer》2014年第9期421-433,共13页

摘　　要：The adoptive transfer of T cells is a promising approach to treat cancers. Primary human T cells can be modified using viral and non-viral vectors to promote the specific targeting of cancer cells via the introduction of exogenous T-cell receptors(TCRs) or chimeric antigen receptors(CARs). This gene transfer displays the potential to increase the specificity and potency of the anticancer response while decreasing the systemic adverse effects that arise from conventional treatments that target both cancerous and healthy cells. This review highlights the generation of clinical-grade T cells expressing CARs for immunotherapy, the use of these cells to target B-cell malignancies and, particularly, the first clinical trials deploying the Sleeping Beauty gene transfer system, which engineers T cells to target CD19+ leukemia and non-Hodgkin's lymphoma.The adoptive transfer of T cells is a promising approach to treat cancers. Primary human T cells can be modified using viral and non-viral vectors to promote the specific targeting of cancer cells via the introduction of exogenous T-cell receptors （TCRs） or chimeric antigen receptors （CARs）. This gene transfer displays the potential to increase the specificity and potency of the anticancer response while decreasing the systemic adverse effects that arise from conventional treatments that target both cancerous and healthy cells. This review highlights the generation of clinical-grade T cells expressing CARs for immunotherapy, the use of these cels to target B-cellmalignancies and, particularly, the first clinical trials deploying the Sleeping Beauty gene transfer system, which engineers T cells to target CD19＋ leukemia and non-Hodgkin＇s lymphoma.

关 键 词：T细胞受体 基因治疗 异性 重新编程 抗原 嵌合 基因转移系统 非病毒载体 

分 类 号：R73-36[医药卫生—肿瘤]